ArticleThe Laryngoscope2026
Pregabalin Efficacy in Treatment of Chronic Neurogenic Cough.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pregabalin Efficacy in Treatment of Chronic Neurogenic Cough.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChronic neurogenic cough (CNC) is prevalent in Otolaryngology settings and impactful. Targeted neuromodulators may offer benefits. This longitudinal study of CNC patients taking pregabalin evaluates success of treatment, duration of treatment, and responses in relation to presence of other trigger conditions.
methodsNinety five patients (73% female, mean age 62y [12.5, SD]) treated with pregabalin for CNC were evaluated by patient-reported outcome measures, ratings of cough improvement and ability to discontinue therapy.
resultsPatients presented with mean 3.5 year [2.75 SD] cough duration. Seventy-eight percent of individuals administered pregabalin reported significant cough improvement or resolution, with mean 6.5 weeks [5, SD] of therapy. Significant reduction in HARQ from 32 [11, SD] to 22 [15, SD], [t-4.15, p = 0.0001, d = 0.60], and RSI scores from 21 [8, SD] to 14.4 [8.2, SD], [t = 6.71, p < 0.001, d = 0.75] were seen following treatment, with moderate effect sizes. 17% of patients taking pregabalin did not report improvement, with 1% reporting worsening cough. Side effects requiring discontinuation of therapy were reported in 4% of patients. Presence of hiatal hernia, dysmotility or reflux findings did not change the likelihood of positive response (75% [no findings] vs. 80% [positive findings]). Sex did not affect likelihood of improvement (female 82% vs. male 85%, p = n.s).
conclusionPregabalin is a well-tolerated neuromodulator providing relief of CNC symptoms in patients presenting to an Otolaryngology clinic. Treatment duration of 6 weeks provides relief to more than three quarters of patients and response to therapy occurs equally across genders and in those with gastrointestinal comorbidities. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.